Literature DB >> 32374384

Roles and challenges of primary care physicians facing a dual outbreak of COVID-19 and dengue in Singapore.

Lawrence T M Lam1, Ying Xian Chua1, David H Y Tan1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32374384      PMCID: PMC7239111          DOI: 10.1093/fampra/cmaa047

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


× No keyword cloud information.
Dear Sir/Madam, Since the start of February 2020, Singapore has been battling a dual outbreak of COVID-19 and dengue with both conditions having similar presentations. Dengue is endemic in Singapore and as of 9 April 2020, there are 5091 confirmed cases of dengue and 98 active clusters (1). The number of COVID-19 cases in Singapore has risen exponentially, with 1910 confirmed cases currently (2). This poses a great challenge within primary care and provides a poignant reminder to primary care providers to keep up with epidemiological trends and rapidly evolving case definitions when confronting a novel pandemic. We share our experience in managing this dual outbreak after two COVID-19 cases had false-positive dengue serology (3). This presented a diagnostic challenge with both conditions presenting with an acute febrile phase together with mild and undifferentiated symptoms. We also briefly discuss the health-seeking behaviours of the first 162 locally transmitted cases in Singapore and the steps taken in Singapore to reduce community transmission. These include the reactivation of the Public Health Preparedness Clinics (PHPC) which provides government subsidized consultation and treatment for patients diagnosed with respiratory illnesses and hence, encouraging the public to seek medical attention early and to reduce doctor hopping.

Managing a dual outbreak

The early stages of COVID-19 infections closely resemble that of dengue and other common respiratory viruses. Other vector-borne diseases such as Zika and Chikungunya also share similar presentations of fever, myalgia, leucopenia and thrombocytopenia and are usually difficult to distinguish clinically from dengue (4,5). While these diseases share similar incubation periods with an acute febrile phase, respiratory symptoms of cough and dyspnoea should raise the clinical suspicion and prompt testing for COVID-19 (6–9). As it is important to differentiate patients presenting with acute febrile illnesses early, we relied on earlier testing of dengue serology on day 3 of illness to rule out dengue infection. Singapore uses Standard Diagnostics (SD) BIOLINE kit which has an overall sensitivity of 93.9% [95% confidence interval (CI) 88.8–96.8%] and specificity of 92.0% (95% CI 81.2–96.9%) (10). As point-of-care testing for COVID-19 was not available at our clinic, we referred patients with prolonged fever and a negative dengue serology for COVID-19 testing. As Singapore had only reported 10 Chikungunya cases and 1 Zika case during the same period with no active clusters reported, we did not test for both these viruses as the management would have been supportive (11).

Challenges and discussion

We highlight the diagnostic challenge of COVID-19 in primary care, especially when facing a concurrent outbreak of an endemic local disease. The early stages of COVID-19 infections are virtually identical to other common viral infections, with many patients initially presenting with mild and undifferentiated symptoms (12). There is a role for early laboratory investigations and serological testing of local endemic conditions to narrow the list of differentials. Significant thrombocytopenia is atypical for COVID-19 infections, observed in only 5–12% of clinical cases but is a prominent feature of dengue (6–9). Most patients with COVID-19 have mild respiratory symptoms though some develop dyspnoea at around 5–7 days from onset of symptoms (8,13). Therefore, primary care physicians need to be abreast of current epidemiological trends, case definitions and recognize when there are variations in disease and symptomatology patterns. Within the climate of a novel infectious disease pandemic, we need to be aware of concomitant diseases and false-positive serology. Primary care providers should consider testing patients with persistent fever without a clear source for COVID-19 as earlier identification is key for containment. Nine hundred and forty-two PHPCs were reactivated, increasing accessibility to primary care and encouraging the public to seek prompt medical attention, resulting in 71% of confirmed COVID-19 patients visiting a primary care doctor within 2 days of symptom onset where symptoms are mild and undifferentiated (2). Twenty-eight percent of these patients visited more than one primary care provider before getting diagnosed. Thirty-two percent of patients were identified at primary care, with the majority of cases referred during the first (37%) and second visit (31%) (2). The average number of days between the initial primary care consult to admission and subsequent diagnosis was 5 days, in keeping with the clinical progression of COVID-19 (13). This could be shorter than other countries due to accessibility of health care and local health-seeking behaviours. With ongoing widespread local transmission, travel history becomes less relevant and without any rapid point-of-care testing, we must rely on symptoms, contact history and maintain a high index of suspicion. We need to be cognizant of patients who have a prolonged duration of illness, especially fever (72%) and cough (83%) with multiple visits (12). If patients can be encouraged to keep to a single provider, either through financial reimbursement measures or assigning patients to a primary care provider, doctors will then be able to fully appreciate their symptom progression and have a better diagnostic yield. The subsequent availability of COVID-19 swabs in our public primary care clinic has allowed our primary care doctors a ‘swab and send home’ strategy, alleviating the load off tertiary institutions by allowing symptomatic patients to rest at home in isolation while their swab results are pending. We are furthering the cause of the battle against COVID-19 by also validating new point-of-care test kits against the gold standard PCR swabs that we are currently carrying out.

Conclusion

Currently, there is an unprecedented strain on health care systems worldwide. Primary care doctors will continue to play a key role in early identification and containment of this pandemic. We must obtain accurate contact and epidemiological history based on evolving local cluster transmissions and be alert to the possibility of false positives and multiple infections. Early testing for local endemic conditions should be considered. As most countries are now facing sustained community transmission, there is a need to shift towards rapid and reliable point-of-care testing for COVID-19 and endemic infections, and primary care facilities can help in validating new test kits that are rapidly being made available.
  9 in total

Review 1.  Zika Virus.

Authors:  Lyle R Petersen; Denise J Jamieson; Ann M Powers; Margaret A Honein
Journal:  N Engl J Med       Date:  2016-03-30       Impact factor: 91.245

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

Review 3.  Chikungunya fever: an epidemiological review of a re-emerging infectious disease.

Authors:  J Erin Staples; Robert F Breiman; Ann M Powers
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

4.  Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.

Authors:  Barnaby Edward Young; Sean Wei Xiang Ong; Shirin Kalimuddin; Jenny G Low; Seow Yen Tan; Jiashen Loh; Oon-Tek Ng; Kalisvar Marimuthu; Li Wei Ang; Tze Minn Mak; Sok Kiang Lau; Danielle E Anderson; Kian Sing Chan; Thean Yen Tan; Tong Yong Ng; Lin Cui; Zubaidah Said; Lalitha Kurupatham; Mark I-Cheng Chen; Monica Chan; Shawn Vasoo; Lin-Fa Wang; Boon Huan Tan; Raymond Tzer Pin Lin; Vernon Jian Ming Lee; Yee-Sin Leo; David Chien Lye
Journal:  JAMA       Date:  2020-04-21       Impact factor: 56.272

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.

Authors:  Xiao-Wei Xu; Xiao-Xin Wu; Xian-Gao Jiang; Kai-Jin Xu; Ling-Jun Ying; Chun-Lian Ma; Shi-Bo Li; Hua-Ying Wang; Sheng Zhang; Hai-Nv Gao; Ji-Fang Sheng; Hong-Liu Cai; Yun-Qing Qiu; Lan-Juan Li
Journal:  BMJ       Date:  2020-02-19

7.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

8.  Diagnosing dengue at the point-of-care: utility of a rapid combined diagnostic kit in Singapore.

Authors:  Victor C Gan; Li-Kiang Tan; David C Lye; Kwoon-Yong Pok; Shi-Qi Mok; Rachel Choon-Rong Chua; Yee-Sin Leo; Lee-Ching Ng
Journal:  PLoS One       Date:  2014-03-19       Impact factor: 3.240

9.  Covert COVID-19 and false-positive dengue serology in Singapore.

Authors:  Gabriel Yan; Chun Kiat Lee; Lawrence T M Lam; Benedict Yan; Ying Xian Chua; Anita Y N Lim; Kee Fong Phang; Guan Sen Kew; Hazel Teng; Chin Hong Ngai; Li Lin; Rui Min Foo; Surinder Pada; Lee Ching Ng; Paul Anantharajah Tambyah
Journal:  Lancet Infect Dis       Date:  2020-03-04       Impact factor: 25.071

  9 in total
  19 in total

Review 1.  Dengue Infection - Recent Advances in Disease Pathogenesis in the Era of COVID-19.

Authors:  Yean Kong Yong; Won Fen Wong; Ramachandran Vignesh; Indranil Chattopadhyay; Vijayakumar Velu; Hong Yien Tan; Ying Zhang; Marie Larsson; Esaki M Shankar
Journal:  Front Immunol       Date:  2022-07-06       Impact factor: 8.786

2.  COVID-19 preparedness among public and healthcare providers in the initial days of nationwide lockdown in India: A rapid electronic survey.

Authors:  Limalemla Jamir; Shaista Najeeb; Rajeev Aravindakshan
Journal:  J Family Med Prim Care       Date:  2020-09-30

3.  COVID-19 and Plasmodium vivax malaria co-infection.

Authors:  Sundus Sardar; Rohit Sharma; Tariq Yousef Mohammad Alyamani; Mohamed Aboukamar
Journal:  IDCases       Date:  2020-06-20

Review 4.  What Is the Impact of Lockdowns on Dengue?

Authors:  Oliver Brady; Annelies Wilder-Smith
Journal:  Curr Infect Dis Rep       Date:  2021-01-21       Impact factor: 3.663

5.  COVID-19 Global Humanitarian Response Plan: An optimal distribution model for high-priority countries.

Authors:  Ibrahim M Hezam
Journal:  ISA Trans       Date:  2021-04-09       Impact factor: 5.911

6.  Impact of concurrent epidemics of dengue, chikungunya, zika, and COVID-19.

Authors:  Creuza Rachel Vicente; Theresa Cristina Cardoso da Silva; Larissa Dell'Antonio Pereira; Angelica E Miranda
Journal:  Rev Soc Bras Med Trop       Date:  2021-02-26       Impact factor: 1.581

7.  Geographical Profiles of COVID-19 Outbreak in Tokyo: An Analysis of the Primary Care Clinic-Based Point-of-Care Antibody Testing.

Authors:  Morihito Takita; Tomoko Matsumura; Kana Yamamoto; Erika Yamashita; Kazutaka Hosoda; Tamae Hamaki; Eiji Kusumi
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec

8.  Low risk of serological cross-reactivity between dengue and COVID-19.

Authors:  Michele Spinicci; Alessandro Bartoloni; Antonia Mantella; Lorenzo Zammarchi; Gian Maria Rossolini; Alberto Antonelli
Journal:  Mem Inst Oswaldo Cruz       Date:  2020-08-14       Impact factor: 2.743

Review 9.  Trajectory of the COVID-19 pandemic: chasing a moving target.

Authors:  Kamal Kant Sahu; Ajay Kumar Mishra; Amos Lal
Journal:  Ann Transl Med       Date:  2020-06

10.  COVID-19 and arboviral diseases: Another challenge for Pakistan's dilapidated healthcare system.

Authors:  Usman A Awan; Sarmad Zahoor; Ayesha Ayub; Haroon Ahmed; Nauman Aftab; Muhammad S Afzal
Journal:  J Med Virol       Date:  2020-12-01       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.